CIN : L24100HR2011PLC114093
Fabino Enterprises Ltd.
(Formerly known as Fabino Life Sciences Ltd.)
(An ISO 9001:2015 Certified Company)

To,
The Manager Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai – 400001.

SCRIP CODE: 543444

Subject: Outcome of meeting of the Board of Directors of Fabino Enterprises Limited held on November 12, 2026

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, we wish to inform you that the Board of Directors of the Company, at its meeting held today i.e. November 12, 2026, has inter alia, approved the following:

1. Approved the Unaudited Standalone and Consolidated Financial Results of the Company for the half year ended on September 30, 2026 pursuant to Regulation 33 of SEBI LODR, Regulations, 2015 and taken on record "Limited Review Report" issued by **M/s. DGMS & Co.**, Statutory Auditor of the Company, with an unmodified opinion.

The Meeting of the Board of Directors of the Company commenced at 04:00 P.M. (IST) and concluded at 04:45 P.M. (IST).

You are requested to take the above information on records and disseminate the same on your website.

Thanks & Regards,
For Fabino Enterprises Limited
(Formerly known as Fabino Life Sciences Limited)

Aditya Mahavir Jain
Digitally signed by Aditya Mahavir Jain
Date: 2026.11.12 17:57:39 +05'30'

Aditya Mahavir Jain
Managing Director
DIN: 09353344

Date: 12.11.2026
Place: Sonipat, Haryana

Encl:
1. Standalone Financial Results including Limited Review Report by Auditor
2. Consolidated Financial Results including Limited Review Report by Auditor.

D G M S & Co.
Chartered Accountants

Hiren J. Maru
B.Com., F.C.A., DISA, DIRM

AUDITORS LIMITED REVIEW REPORT ON UNAUDITED STANDALONE FINANCIAL RESULTS OF THE COMPNAY FOR THE HALF YEAR ENDED 30th SEPTEMBER 2026 PURSUANT TO THE REGULATION 33 OF THE SEBI (LISTINGOBLIGATION AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 AS AMENDED.

To Board of Directors of
FABINO ENTERPRISES LIMITED
(Formerly known as Fabino Life Sciences Limited)

We have reviewed the accompanying statement of unaudited standalone financial results ("the statement") of **FABINO ENTERPRISES LIMITED** (formerly known as Fabino Life Sciences Limited) ('the Company") for the half year ended 30th September 2026 being submitted by the company pursuant to the requirement of Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries primarily of person responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statements of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulations 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

FOR D G M S & CO.
Chartered Accountants
Firm Regn. No. 0112187W

D G M S & CO. FRN: 0112187W Chartered Accountants

Hiren J Maru
Partner
Membership No. 115279
UDIN: 26115279XZINJW4082

Date: 12th November 2026
Place: Mumbai

Office Address: Office No. 10, Vihang Vihar, Opp. Gautam Park, Panchpakhadi, Thane (West) – 400 602, Maharashtra, India.
Cell: +91 9320268900 Ph.: 022 4601 2965 / 2545 2965 Email: hirenmaru@yahoo.co.uk

FABINO ENTERPRISES LIMITED

(Formerly known as FABINO LIFE SCIENCES LIMITED)

CIN: L24100HR2011PLC114093

Registered Office: Jeevan Vihar Extension, Nr Shubham Garden, Murthal Road, Sonipat Haryana 131001

Statement of Standalone Unaudited Financial Results for the Half Year and Year Ended 30.09.2026

(Rupees in lakhs)

	Particulars	Half Year Ended			Year Ended
		30-09-2026	31-03-2026	30-09-2025	31-03-2026
A	Date of start of reporting period	01-04-2026	01-10-2025	01-04-2025	01-04-2025
B	Date of end of reporting period	30-09-2026	31-03-2026	30-09-2025	31-03-2026
C	Whether results are audited or unaudited	Unaudited	Unaudited	Unaudited	Audited
Part I					
I	**Revenue From Operations**				
	Net sales or Revenue from Operations	0.64	1,074.80	67.99	1,142.79
II	Other Income	67.85	115.59	14.60	130.19
III	**Total Revenue (I + II)**	**68.49**	**1,190.39**	**82.59**	**1,272.98**
IV	**Expenses**				
(a)	Direct Expenses	5.81	9.00	-	9.00
(b)	Purchases of stock-in-trade	0.00	1,135.24	20.48	1155.72
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	93.15	(20.09)	47.24	27.15
(d)	Employee benefit expense	1.34	2.43	10.38	12.81
(e)	Finance Costs	0.52	4.66	8.10	12.77
(f)	Depreciation and amortisation expense	4.55	5.03	5.33	10.36
(g)	Other Expenses	46.12	77.17	15.59	92.76
	Total expenses	**151.49**	**1,213.43**	**107.13**	**1,320.56**
V	**Profit (loss) before Exceptional and Extraordinary Items and tax (III-IV)**	**(83.00)**	**(23.04)**	**(24.55)**	**(47.59)**
VI	Exceptional items				
VII	Share of Profit/(Loss) of Associates				
VIII	**Profit (loss) before Tax (VII-VIII)**	**(83.00)**	**(23.04)**	**(24.55)**	**(47.59)**
X	**Tax Expense**				
(a)	Current Tax	0.00	-	0.00	-
	(Less):- MAT Credit				
	Current Tax Expense Relating to Prior years				
(b)	Deferred Tax (Asset)/Liabilities	(22.91)	(11.94)	0.33	(11.62)
XI	**Net Profit/Loss for the period from Continuing Operations (IX-X)**	**(60.09)**	**(11.09)**	**(24.87)**	**(35.97)**
XII	Profit (Loss) from Discontinuing Operaitons				
XIII	Tax Expenses of Discontinuing Operations				
XIV	**Net Profit (Loss) from Discontinuing Operartions after tax (XII-XIII)**	-	-	-	-
XV	**Profit (Loss) for the period (XI+XIV)**	**(60.09)**	**(11.09)**	**(24.87)**	**(35.97)**
XVI	**Other Comprehensive Income**				
	a . i).Amount of item that will not be reclassifed to profit or loss				
	ii). Income tax relating to items that will not be reclassifed to profit or loss				
	b i). Item that will be reclassifed to profit or loss				
	ii). Income tax relating to items that will be reclassifed to profit or loss				
XVII	**Total Comprehensive income**				
	Total Comprehensive income [Comprising Profit for the Period (After tax) and Other comprehensive income] (XV+XVII)	-	-	-	-
XVIII	**Details of equity share capital**	**(60.09)**	**(11.09)**	**(24.87)**	**(35.97)**
	Paid-up equity share capital (Face Value of Rs. 10/- per equity share)	210.00	210.00	210.00	210.00
	Face value of equity share capital (Per Share)	Rs. 10/-	Rs. 10/-	Rs. 10/-	Rs. 10/-
XIX	**Reserves excluding revaluation reserve as per Balance Sheet**				
XX	**Earnings per share (Not Annualized for Half Year and Year ended)**	**-2.86**	**-0.53**	**-1.18**	**-1.71**
(a)	**Earnings per share Continuing Operation (Not Annualised for Half Year and Year ended)**				
	Basic earnings per share before extraordinary items	(2.86)	(0.53)	(1.18)	-1.71
	Diluted earnings per share before extraordinary items	(2.86)	(0.53)	(1.18)	-1.71
(b)	**Earnings per share Discontinuing Operation (Not Annualised for Half Year and Year ended)**				
	Basic earnings per share after extraordinary items	-	-	-	-
	Diluted earnings per share after extraordinary items	-	-	-	-
(c)	**Earnings per share (Not Annualised for Half Year and Year ended)**				
	Basic earnings per share before extraordinary items	(2.86)	(0.53)	(1.18)	-1.71
	Diluted earnings per share before extraordinary items	(2.86)	(0.53)	(1.18)	-1.71

Notes:-

Notes to Standalone Unaudited financials results for the half year ended September 30, 2026

1. The above Unaudited financial results are as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and taken on record by
2. The company has been lisited on SME platform of Bse on 13th January 2022.
3. The aforesaid Half yearly Financial Results are also being disseminated on the website of the Company i.e. (https://www.fabinolife.com/fabino-ipo/)
4. The figures for the corresponding previous period have been regrouped/ reclassified wherever necessary, to make them comparable.

FOR FABINO ENTERPRISES LIMITED
(Formerly known as Fabino Life Sciences Limited)

Aditya Mahavir Jain
Managing Director
DIN: 09353344

Date: 12th November 2026
Place :- Haryana

Scanned with OKEN Scanner

FABINO ENTERPRISES LIMITED

(Formerly known as FABINO LIFE SCIENCES LIMITED)

Registered Office: Jeevan Vihar Extension, Nr Shubham Garden, Murthal Road, Sonipat Haryana 131001
CIN: L24100HR2011PLC114093

STANDALONE BALANCE SHEET AS AT 30th SEPTEMBER, 2026

(Rupees in Lakhs)

	Figures as at the end of current reporting period September 30, 2026	*Figures as at the end of reporting period March 31, 2026*
I. EQUITY AND LIABILITIES		
(1) Shareholder's Funds		
(a) Share Capital	210.00	210.00
(b) Reserves and Surplus	122.84	182.93
(c) Money received against share warrants	-	-
(2) Share Application money pending allotment		
(3) Non-Current Liabilities		
(a) Long-Term Borrowings	10.15	111.25
(b) Deferred Tax Liabilities (Net)		-
(c) Other Long Term Liabilities	-	-
(d) Long Term Provisions		-
(4) Current Liabilities		
(a) Short-Term Borrowings	-	-
(b) Trade Payables		
-Micro, Small and Medium Enterprises	-	
-Others	907.56	1,214.07
(c) Other Current Liabilities	1.58	5.94
(d) Short-Term Provisions	7.67	8.12
Total Equity & Liabilities	**1,259.81**	**1,732.31**
II.ASSETS		
(1) Non-Current Assets		
(a) Fixed Assets		
(i) Tangible Assets	8.50	37.45
(ii) Intangible Assets	-	-
(iii) Capital work-in-progress	-	-
(iv) Intangible Assets under development	-	-
(v) Fixed assets held for sale	-	-
	8.50	37.45
(b) Non-current investments	5.00	5.00
(c) Deferred tax Assets (net)	35.37	12.46
(c) Long term loans and advances	-	-
(d) Other non-current assets	-	3.91
(2) Current Assets		
(a) Current investments		
(b) Inventories	-	93.15
(c) Trade receivables	1,105.58	1,267.84
(d) Cash and cash equivalents	22.60	16.39
(e) Short-term loans and advances	67.45	105.46
(f) Other current assets	15.31	190.66
Total Assets	**1,259.81**	**1,732.31**

FOR FABINO ENTERPRISES LIMITED
(Formerly known as Fabino Life Sciences Limited)

Date: 12th November 2026
Place : Haryana

Aditya Mahavir Jain
Managing Director
DIN: 09353344

Scanned with OKEN Scanner

FABINO ENTERPRISES LIMITED

(Formerly known as FABINO LIFE SCIENCES LIMITED)
Registered Office: Jeevan Vihar Extension, Nr Shubham Garden, Murthal Road, Sonipat Haryana 131001
CIN: L24100HR2011PLC114093

STANDALONE CASH FLOW STATEMENT AS AT 30th SEPTEMBER, 2026

(Rupees in lakhs)

Particulars	*Figures as at the end of current reporting period September 30, 2026*	*Figures as at the end of reporting period March 31, 2026*
(A) Cash flows from operating activities		
Profit for the year	(83.00)	(47.59)
- Finance costs	0.52	12.77
- Income tax Provision		-
Adjustments for non-cash income and expenses:		
-Depreciation & Amortisation	4.55	10.36
-Loss/(Profit) on sale/disposal of Fixed Assets	17.15	-
Cash flow included in investing activities:		
- Interest Income	-	-
Changes in operating assets and liabilities:		
- Decrease / (Increase) in Inventory	93.15	27.15
- Decrease / (Increase) in Trade Receivables	162.26	(406.28)
- Decrease / (Increase) in Other Current Assets	175.35	(66.89)
- Decrease / (Increase) in Other Non Current Assets	3.91	2.45
- Decrease / (Increase) in Short Term loans & Advances	38.01	9.21
- (Decrease) / Increase in Short Term Borrowings	-	-
- (Decrease) / Increase in Trade Payables	(306.51)	567.42
- (Decrease) / Increase in Short Term Provisions	(0.46)	(6.06)
- (Decrease) / Increase in Other Current Liabilities	(4.35)	(43.74)
Cash generated from operations	100.58	58.80
Income tax paid		-
Net cash from operating activities	100.58	58.80
(B) Cash flows from investing activities		
Sale of Fixed Assets	7.26	-
Investment in Shares	-	-
Interest received / (Paid)	(0.52)	
Purchase of Fixed Assets		(1.42)
Net cash from investing activities	6.74	(1.42)
(C) Cash flows from financing activities		
Proceeds from Share Capital	-	
Interest received / (Paid)	-	(12.77)
Proceeds/(Repayment) from Long-term borrowings	(101.10)	(49.98)
Proceeds/(Repayment) of Other Long Current liabilities		
Net cash from financing activities	(101.10)	(62.75)
Net increase / (decrease) in cash and cash equivalents	6.22	(5.37)
Cash and cash equivalents at the beginning of year	16.39	**21.76**
Cash and cash equivalents at the end of year	**22.60**	**16.39**

FOR FABINO ENTERPRISES LIMITED
(Formerly known as Fabino Life Sciences Limited)

Aditya Mahavir Jain
Managing Director
DIN: 09353344

Date: 12th November 2026
Place : Haryana

Scanned with OKEN Scanner

D G M S & Co.
Chartered Accountants

Hiren J. Maru
B.Com., F.C.A., DISA, DIRM

AUDITORS LIMITED REVIEW REPORT ON UNAUDITED CONSOLIDATED FINANCIAL RESULT OF THE COMPNAY FOR THE HALF YEAR ENDED 30th SEPTEMBER 2026 PURSUANT TO THE REGULATION 33 OF THE SEBI (LISTING OBLIGATION AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 AS AMENDED.

To Board of Directors of
FABINO ENTERPRISES LIMITED
(Formerly known as Fabino Life Sciences Limited)

We have reviewed the accompanying statement of unaudited Consolidated financial results ("the statement") of Holding Company **FABINO ENTERPRISES LIMITED** (formerly known as Fabino Life Sciences Limited) ('the Company") for the half year ended 30th September 2026 and its Subsidiary Company **UPENDER METAPLAST PRIVATE LIMITED** for the half year ended 30th September 2026 being submitted by the company pursuant to the requirement of Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. This Statement is the responsibility of the company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries primarily of person responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statements of unaudited consolidated financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulations 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

FOR D G M S & CO.
Chartered Accountants
Firm Regn. No. 0112187W

D G M S & CO. FRN: 0112187W Chartered Accountants

Hiren J Maru
Partner
Membership No. 115279
UDIN: 26115279UGZVKY7431

Date: 12th November 2026
Place: Mumbai

Office Address: **Office No. 10, Vihang Vihar, Opp. Gautam Park, Panchpakhadi, Thane (West) – 400 602, Maharashtra, India.**
Cell: +91 9320268900 Ph.: 022 4601 2965 / 2545 2965 Email: hirenmaru@yahoo.co.uk

FABINO ENTERPRISES LIMITED

(Formerly known as FABINO LIFE SCIENCES LIMITED)

CIN: L24100HR2011PLC114093

Registered Office: Jeevan Vihar Extension, Nr Shubham Garden, Murthal Road, Sonipat Haryana 131001

Statement of Consolidated Unaudited Financial Results for the Half Year and Year Ended 30.09.2026

(Rupees in lakhs)

	Particulars	Half Year Ended			(Rupees in lakhs) Year Ended
A	Date of start of reporting period	30-09-2026	31-03-2026	30-09-2025	31-03-2026
B	Date of end of reporting period	01-04-2026	01-10-2025	01-04-2025	01-04-2025
C	Whether results are audited or unaudited	30-09-2026	31-03-2026	30-09-2025	31-03-2026
Part I		Unaudited	Unaudited	Unaudited	Audited
I	**Revenue From Operations**				
	Net sales or Revenue from Operations	153.61	1420.71	663.34	2084.06
II	Other Income	67.85	128.83	27.56	156.39
III	**Total Revenue (I + II)**	**221.47**	**1,549.54**	**690.90**	**2,240.44**
IV	**Expenses**				
(a)	Direct Expenses	22.85	124.30	-	124.30
(b)	Purchases of stock-in-trade	126.06	1,459.70	546.95	2,006.66
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	106.41	(33.35)	47.24	13.89
(d)	Employee benefit expense	1.34	3.33	10.38	13.71
(e)	Finance Costs	0.52	4.40	8.74	13.14
(f)	Depreciation and amortisation expense	4.55	5.03	5.92	10.95
(g)	Other Expenses	48.72	41.35	90.16	131.52
	Total expenses				
V	**Profit (loss) before Exceptional and Extraordinary Items and tax (III-IV)**	**310.45**	**1,604.76**	**709.40**	**2,314.16**
VI	Exceptional items	**(88.98)**	**(55.22)**	**(18.50)**	**(73.71)**
VII	Share of Profit/(Loss) of Associates				
VIII	**Profit (loss) before Tax (VII-VIII)**				
X	**Tax Expense**	**(88.98)**	**(55.22)**	**(18.50)**	**(73.71)**
(a)	Current Tax				
	(Less):- MAT Credit	-		-	-
	Current Tax Expense Relating to Prior years				
(b)	Deferred Tax (Asset)/Liabilities				
(c)	Prior Period Income Tax Written Off	(26.03)	(18.07)	0.10	(17.97)
XI	**Net Profit/Loss for the period from Continuing Operations (IX-X)**		0.13		0.13
XII	Profit (Loss) from Discontinuing Operaitons	**(62.95)**	**(37.28)**	**(18.59)**	**(55.87)**
XIII	Tax Expenses of Discontinuing Operations				
XIV	**Net Profit (Loss) from Discontinuing Operartions after tax (XII-XIII)**	-	-	-	-
XV	**Profit (Loss) for the period (XI+XIV)**	**(62.95)**	**(37.28)**	**(18.59)**	**(55.87)**
XVI	**Other Comprehensive Income**				
	a . i).Amount of item that will not be reclassifed to profit or loss				
	ii). Income tax relating to items that will not be reclassifed to profit or loss				
	b i). Item that will be reclassifed to profit or loss				
	ii). Income tax relating to items that will be reclassifed to profit or loss				
XVII	**Total Comprehensive Income**				
	Total Comprehensive Income [Comprising Profit for the Period (After tax) and Other comprehensive income] (XV+XVII)	-	-	-	-
XVIII	**Details of equity share capital**	**(62.95)**	**(37.28)**	**(18.59)**	**(55.87)**
	Paid-up equity share capital (Face Value of Rs. 10/- per equity share)	210.00	210.00	210.00	210.00
	Face value of equity share capital (Per Share)	Rs. 10/-	Rs. 10/-	Rs. 10/-	Rs. 10/-
XIX	**Reserves excluding revaluation reserve as per Balance Sheet**				
XX	**Earnings per share (Not Annualized for Half Year and Year ended)**				
(a)	**Earnings per share Continuing Operation (Not Annualised for Half Year and Year ended)**	**-3.00**	**-1.78**	**-0.89**	**-2.66**
	Basic earnings per share before extraordinary items	(3.00)	(1.78)	(0.89)	(2.66)
	Diluted earnings per share before extraordinary items	(3.00)	(1.78)	(0.89)	(2.66)
(b)	**Earnings per share Discontinuing Operation (Not Annualised for Half Year and Year ended)**				
	Basic earnings per share after extraordinary items	-	-	-	-
	Diluted earnings per share after extraordinary items	-	-	-	-
(c)	**Earnings per share (Not Annualised for Half Year and Year ended)**				
	Basic earnings per share before extraordinary items	(3.00)	(1.78)	(0.89)	(2.66)
	Diluted earnings per share before extraordinary items	(3.00)	(1.78)	(0.89)	(2.66)

Notes:-

Notes to Standalone Unaudited financials results for the half year ended September 30, 2026

1. The above Unaudited financial results are as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and taken on record by the Board of Directors at its meeting held on November 12, 2026 after being reviewed by the Audit Committee.
2. The company has been lisited on SME platform of Bse on 13th January 2022.
3. The aforesaid Half yearly Financial Results are also being disseminated on the website of the Company i.e. (https://www.fabinolife.com)
4. The figures for the corresponding previous period have been regrouped/ reclassified wherever necessary, to make them comparable.

FOR FABINO ENTERPRISES LIMITED
(Formerly known as Fabino Life Sciences Limited)

Aditya Mahavir Jain
Managing Director
DIN: 09353344

Date :- 12th November 2026
Place :- Haryana

Scanned with OKEN Scanner

FABINO ENTERPRISES LIMITED

(Formerly known as FABINO LIFE SCIENCES LIMITED)

Registered Office: Jeevan Vihar Extension, Nr Shubham Garden, Murthal Road, Sonipat Haryana 131001
CIN: L24100HR2011PLC114093

Consolidated Balance Sheet as at 30th September 2026

(Rupees in Lakhs)

Particulars	*Figures as at the end of current reporting period September 30, 2026*	*Figures as at the end of reporting period March 31, 2026*
I. EQUITY AND LIABILITIES		
(1) Shareholder's Funds		
(a) Share Capital	210.00	210.00
(b) Reserves and Surplus	91.66	154.61
(c) Money received against share warrants	-	-
(d) Minority Interest	0.00	0.00
(2) Share Application money pending allotment		
(3) Non-Current Liabilities		
(a) Long-Term Borrowings	190.63	162.39
(b) Deferred Tax Liabilities (Net)	-	-
(c) Other Long Term Liabilities	-	-
(d) Long Term Provisions	-	-
(4) Current Liabilities		
(a) Short-Term Borrowings	-	-
(b) Trade Payables		-
-Micro, Small and Medium Enterprises	-	-
-Others	1,076.28	1,647.15
(c) Other Current Liabilities	1.59	30.98
(d) Short-Term Provisions	8.67	9.12
Total Equity & Liabilities	**1,578.83**	**2,214.26**
II.ASSETS		
(1) Non-Current Assets		
(a) Fixed Assets		
(i) Tangible Assets	8.50	37.45
(ii) Intangible Assets	-	-
(iii) Capital work-in-progress	-	-
(iv) Intangible Assets under development	-	-
(v) Fixed assets held for sale	-	-
	8.50	37.45
(b) Non-current investments	-	-
(c) Deferred tax Assets (net)	45.07	19.03
(c) Long term loans and advances	-	-
(d) Other non-current assets	-	3.91
(2) Current Assets		
(a) Current investments	-	-
(b) Inventories	-	106.41
(c) Trade receivables	1,455.02	1,646.32
(d) Cash and cash equivalents	25.22	19.88
(e) Short-term loans and advances	24.19	14.50
(f) Other current assets	20.83	366.76
Total Assets	**1,578.83**	**2,214.26**

FOR FABINO ENTERPRISES LIMITED
(Formerly known as Fabino Life Sciences Limited)

Date :- 12th November 2026
Place : Haryana

Aditya Mahavir Jain
Managing Director
DIN: 09353344

Scanned with OKEN Scanner

FABINO ENTERPRISES LIMITED

(Formerly known as FABINO LIFE SCIENCES LIMITED)

Registered Office: Jeevan Vihar Extension, Nr Shubham Garden, Murthal Road, Sonipat Haryana 131001

CIN: L24100HR2011PLC114093

Consolidated Cash Flow Statement as at 30th September 2026

(Rupees in lakhs)

Particulars	*Figures as at the end of current reporting period September 30, 2026*	*Figures as at the end of reporting period March 31, 2026*
(A) Cash flows from operating activities		
Profit for the year		
- Finance costs	(88.98)	(73.71)
- Income tax Provision	0.52	13.14
Adjustments for non-cash income and expenses:	-	-
-Depreciation & Amortisation		
-Loss/(Profit) on sale/disposal of Fixed Assets	4.55	10.95
Cash flow included in investing activities:	17.15	(0.03)
- Interest Income		
Changes in operating assets and liabilities:	-	-
- Decrease / (Increase) in Inventory		
- Decrease / (Increase) in Trade Receivables	106.41	13.89
- Decrease / (Increase) in Other Current Assets	191.30	(229.30)
- Decrease / (Increase) in Other Non Current Assets	345.93	(255.74)
- Decrease / (Increase) in Short Term loans & Advances	3.91	2.45
- (Decrease) / Increase in Short Term Borrowings	(9.69)	16.13
- (Decrease) / Increase in Trade Payables	-	-
- (Decrease) / Increase in Short Term Provisions	(570.87)	579.97
- (Decrease) / Increase in Other Current Liabilities	(0.45)	(6.06)
Cash generated from operations	(29.39)	(52.87)
Income tax paid	(29.63)	18.80
Net cash from operating activities	-	(0.13)
	(29.63)	18.67
(B) Cash flows from investing activities		
Sale of Fixed Assets		
Interest received / (Paid)	7.26	8.10
Purchase of Fixed Assets		
Net cash from investing activities		(1.42)
	7.26	6.68
(C) Cash flows from financing activities		
Proceeds from Share Capital		
Interest received / (Paid)	-	-
Proceeds/(Repayment) from Long-term borrowings	(0.52)	(13.14)
Proceeds/(Repayment) of Other Long Current liabilities	28.24	(16.71)
Net cash from financing activities		
	27.72	(29.85)
Net increase / (decrease) in cash and cash equivalents	5.34	(4.50)
Cash and cash equivalents at the beginning of year	**19.88**	24.38
Cash and cash equivalents at the end of year	**25.22**	**19.88**

FOR FABINO ENTERPRISES LIMITED

(Formerly known as Fabino Life Sciences Limited)

Date :- 12th November 2026

Place : Haryana

Aditya Mahavir Jain
Managing Director
DIN: 09353344

Scanned with OKEN Scanner